| |
Being a highly fragmented market, goals will be more difficult to realise in Europe. However, with recent improvements, there is enough evidence to believe Europe is steadily moving towards research excellence.
New analysis from Frost & Sullivan (pharma.frost.com), Life Sciences Funding in Europe (2007), finds that funding in the five major European countries – UK, France, Germany, Italy and Spain – totalled €7,732.6 million in 2006.
“European life sciences funding is rising at a healthy pace, driven mainly by the commitment of the European Commission and research-performing nations to boost R&D productivity,” notes Frost & Sullivan Research Analyst John Paul. “In addition to support from the major EU nations, these positive trends are being buttressed by the framework programmes for financing R&D in universities and SMEs.”
Pharma and biotech pipelines do not show encouraging signs and the few companies that shine in the industry have their research base in the United States. Major pharmaceutical companies have been shifting their research base from Europe to the United States, retarding life sciences development across the EU.
Moreover, the European funding landscape is highly fragmented. While several public, private and charity bodies contribute to funding research, the goals and objectives vary among organisations, making it difficult to maximise on results.
“With varying policies across Europe, there is a risk of replication and hence, wastage of money and effort,” explains Paul. “At the moment, there is not enough communication across the EU to promote a coordinated effort towards achieving research goals. The initiatives established by the EU cover projects that are too large to manage and coordinate among the large number of participating countries.”
Europe needs to streamline its research policies and goals to optimise on the output of R&D in life sciences. Funding made available for SMEs and other individual projects has to be enhanced in size to support late-stage development phases.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the life sciences funding in Europe, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.
Life Sciences Funding in Europe (2007) is part of the Pharmaceutical and Clinical Diagnostics Growth Partnership Service Programme, which also includes research in the following markets: European Bladder Cancer Therapeutics Market, European Gastroenterology Therapeutics Market, European Prostrate Cancer Therapeutics Market, European Head and Neck Cancer Therapeutics Market and European Testosterone Replacement Therapies Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.
Life Sciences Funding in Europe (2007) M1E0
|
patrick.cairns[.]frost.com 
